Cargando…

Tumour-marker levels and prognosis in malignant teratoma of the testis.

The effect of 6 putative prognostic factors on survival was studied in patients with Stages III and IV malignant teratoma of the testis. Differences between survival curves were tested for statistical significance. A diameter greater than 5 cm in the largest tumour mass, and greater than 8 pulmonary...

Descripción completa

Detalles Bibliográficos
Autores principales: Germa-Lluch, J. R., Begent, R. H., Bagshawe, K. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1980
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010592/
https://www.ncbi.nlm.nih.gov/pubmed/6161630
_version_ 1782136354717564928
author Germa-Lluch, J. R.
Begent, R. H.
Bagshawe, K. D.
author_facet Germa-Lluch, J. R.
Begent, R. H.
Bagshawe, K. D.
author_sort Germa-Lluch, J. R.
collection PubMed
description The effect of 6 putative prognostic factors on survival was studied in patients with Stages III and IV malignant teratoma of the testis. Differences between survival curves were tested for statistical significance. A diameter greater than 5 cm in the largest tumour mass, and greater than 8 pulmonary metastases were adverse prognostic factors (P = 0.004 and 0.008 respectively). Patients with malignant teratoma, trophoblastic, fared worse than those with malignant teratoma, undifferentiated, and malignant teratoma, intermediate (P = 0.011 and 0.023 respectively). Previous chemotherapy or radiotherapy had no significant effect. Serum alpha-foetoprotein (AFP) above 10(3) MRC u/ml and serum beta subunit of human chorionic gonadotrophin (hCG) above 10(5) miu/ml, were found to predict a poor prognosis (P = 0.010 and 0.001 respectively). A combination of measurements of the tumour markers gave the most consistent indication of prognosis, in that patients with either AFP greater than 10(3) MRC u/ml or hCG greater than 10(5) miu/ml, or both, fared much worse than those with neither factor (P = 0.001). Serum concentrations of AFP and hCG should be stated in reports of treatment of testicular teratoma in order to provide a basis for comparison with other series. Regular and frequent measurements of these markers are appropriate throughout the clinical management of patients with malignant teratoma.
format Text
id pubmed-2010592
institution National Center for Biotechnology Information
language English
publishDate 1980
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20105922009-09-10 Tumour-marker levels and prognosis in malignant teratoma of the testis. Germa-Lluch, J. R. Begent, R. H. Bagshawe, K. D. Br J Cancer Research Article The effect of 6 putative prognostic factors on survival was studied in patients with Stages III and IV malignant teratoma of the testis. Differences between survival curves were tested for statistical significance. A diameter greater than 5 cm in the largest tumour mass, and greater than 8 pulmonary metastases were adverse prognostic factors (P = 0.004 and 0.008 respectively). Patients with malignant teratoma, trophoblastic, fared worse than those with malignant teratoma, undifferentiated, and malignant teratoma, intermediate (P = 0.011 and 0.023 respectively). Previous chemotherapy or radiotherapy had no significant effect. Serum alpha-foetoprotein (AFP) above 10(3) MRC u/ml and serum beta subunit of human chorionic gonadotrophin (hCG) above 10(5) miu/ml, were found to predict a poor prognosis (P = 0.010 and 0.001 respectively). A combination of measurements of the tumour markers gave the most consistent indication of prognosis, in that patients with either AFP greater than 10(3) MRC u/ml or hCG greater than 10(5) miu/ml, or both, fared much worse than those with neither factor (P = 0.001). Serum concentrations of AFP and hCG should be stated in reports of treatment of testicular teratoma in order to provide a basis for comparison with other series. Regular and frequent measurements of these markers are appropriate throughout the clinical management of patients with malignant teratoma. Nature Publishing Group 1980-12 /pmc/articles/PMC2010592/ /pubmed/6161630 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Germa-Lluch, J. R.
Begent, R. H.
Bagshawe, K. D.
Tumour-marker levels and prognosis in malignant teratoma of the testis.
title Tumour-marker levels and prognosis in malignant teratoma of the testis.
title_full Tumour-marker levels and prognosis in malignant teratoma of the testis.
title_fullStr Tumour-marker levels and prognosis in malignant teratoma of the testis.
title_full_unstemmed Tumour-marker levels and prognosis in malignant teratoma of the testis.
title_short Tumour-marker levels and prognosis in malignant teratoma of the testis.
title_sort tumour-marker levels and prognosis in malignant teratoma of the testis.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010592/
https://www.ncbi.nlm.nih.gov/pubmed/6161630
work_keys_str_mv AT germalluchjr tumourmarkerlevelsandprognosisinmalignantteratomaofthetestis
AT begentrh tumourmarkerlevelsandprognosisinmalignantteratomaofthetestis
AT bagshawekd tumourmarkerlevelsandprognosisinmalignantteratomaofthetestis